Citation:Mayer R, Ohtsu A, Yoshino T, et al. 2016

Citation

Mayer R, Ohtsu A, Yoshino T, et al.. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. J Clin Oncol 2016;34:Abstr 634.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Systemic options for third-line treatment